Pharma and healthcare marketing used to be built around a relatively stable rhythm: launch planning, salesforce alignment, medical congresses, HCP education, patient support, access materials, field-force enablement, and, in the US, direct-to-consumer advertising.
That rhythm has broken. Totally.
Healthcare marketing is now being reshaped by a stack of forces that move faster than most medical, regulatory, creative, and procurement processes were designed to handle: AI (especially the impact of GEO), omnichannel HCP engagement, consumer self-diagnosis, influencer-led health conversations, supply-chain fragility, rising media complexity, cost pressure, health inequity, and a more volatile geopolitical environment.
The US sits at the centre of this acceleration. It is the world’s most commercially significant healthcare market, and one of the few where prescription medicines can be advertised directly to consumers. But the implications are global. HCPs, patients, caregivers, payers, regulators, advocacy groups and influencers are all operating in a more connected, sceptical and information-dense marketplace.
For pharma, medtech, diagnostics, consumer health, private healthcare providers and digital health brands, the operating model question is no longer: “How do we run better campaigns?”
It is: “How do we build a marketing ecosystem that can sense, decide, create, approve, deploy, measure and optimise faster — without losing trust, compliance or scientific credibility?”
That requires a more “bionic ecosystem”: the right combination of human expertise, agency capability, data, AI, other technology, governance and culture.
Why pharma and healthcare marketing models are accelerating
There are six big accelerants.
First, healthcare demand is growing. IQVIA forecasts that global medicine spending, at list prices, will continue to rise materially through 2029, with the US outlook higher than previous estimates. Growth is being driven by increased use of innovative medicines, specialty therapies, obesity treatments, oncology, immunology, rare disease and broader patient access in many markets. [1]
Second, the customer journey has fragmented. HCPs still rely on peer evidence, journals, congresses, reps and medical education. But they also expect digital convenience (GEO especially), high-quality content, personalised engagement and credible scientific support on their terms. Patients and caregivers are no longer passive recipients of information; they search, compare, discuss, challenge and advocate. GEO has effectively collapsed the customer journey “funnel”.
Third, the US DTC environment is under more scrutiny. The FDA’s clear, conspicuous and neutral final rule for TV and radio prescription drug ads has raised the bar for risk communication, and recent US policy attention has increased pressure on pharmaceutical advertising, including digital and influencer activity. [2]
Fourth, health information is now social. KFF found that 55% of US adults use social media for health information and advice at least occasionally, while 36% of those who use social media for health information say there is a particular influencer they trust. That creates opportunity, but also risk: misinformation, undisclosed sponsorships, anecdotal claims, adverse-event visibility and fast-moving reputational exposure. [3]
Fifth, AI is changing the economics of marketing operations. AI is already affecting content creation, modular asset production, HCP targeting, next-best-action, medical review workflows, segmentation, call planning, search behaviour, synthetic research and performance optimisation. Digital Health Coalition research found strong industry interest in generative AI for consumer marketing, patient support and patient customer experience. [4]
Sixth, geopolitics has returned to the operating model. The war in Iran has sharpened concerns about oil, energy, freight, petrochemicals, API & excipients, packaging, medical plastics and single-use healthcare supplies. UK pharmacy and UK NHS-facing reports have already warned of medicine and medical-product price pressure linked to higher fuel, air freight and petrochemical costs. The lesson for marketers is not to overclaim causality, but to recognise that volatility can quickly affect pricing, availability, launch planning, communications, channel mix and customer expectations. [5]
The pharma and healthcare trends
| Trend | What is changing | Marketing operating model implication |
|---|---|---|
| AI-enabled marketing | GenAI, predictive analytics, content automation, GEO search and decision support are moving from experiments to embedded workflows. | Marketing needs AI governance, approved use cases, new skills, faster content supply chains and clear human accountability. |
| Omnichannel HCP engagement | HCPs expect relevant, timely, evidence-based engagement across rep, remote, congress, email, portals, social, webinars and peer channels. | HCP engagement must be designed around journeys, not channels or brand teams. Field, medical, marketing and agencies need tighter orchestration. |
| Consumer-led health behaviour | Patients and caregivers research symptoms, compare treatments, use communities and challenge professional advice. | Brands need better patient education, search, social listening, community understanding and content mapped to moments of need. |
| Influencer and creator health media | Doctors, nurses, patients, caregivers and lifestyle creators shape health beliefs and treatment conversations. | Influencer governance must move beyond media buying into compliance, medical review, disclosure, monitoring and crisis response. |
| Supply-chain and pricing volatility | Energy, freight, APIs, petrochemicals and logistics shocks can affect availability and cost. | Marketing, market access, supply, finance and comms need connected planning so messages reflect real availability, affordability and customer pressure. |
| Specialty, obesity, oncology and rare disease growth | Growth is moving into complex, high-value, high-support categories. | Operating models need deeper scientific content, patient services, HCP education, reimbursement support and ecosystem partnerships. |
| Data privacy and consent pressure | First-party data, identity resolution, consent and health data governance are increasingly important. | Marketing needs strong data taxonomies, clean permissions, compliant measurement and reduced dependency on opaque third-party targeting. |
| Healthcare trust deficit | Misinformation and scepticism are rising, while people still seek authoritative guidance. | Trust must be designed into content, channel choice, claims, evidence, spokesperson strategy and response protocols. |
The practical playbook: V-PRODUCT for pharma and healthcare marketing
V — Vision
Start with a clear commercial and customer vision.
Many healthcare organisations still build marketing plans brand by brand, market by market and channel by channel. That is too slow for the current environment. The vision should define the role of marketing in growth, trust, access, education and patient outcomes.
The strongest vision will connect HCP, patient, payer and caregiver experience into one coherent model.
P — People
Pharma marketing needs different talent.
The future team is not simply more digital of course it needs to understand AI but also data, content operations, medical-regulatory workflows, behavioural science, social influence, customer experience, media performance and agency orchestration.
This means every marketer understands how to work in a bionic system: where human judgement, scientific integrity and AI-enabled productivity reinforce each other.
R — Resources
The agency and external partner ecosystem needs redesign.
Pharma and healthcare brands often have too many agencies, too many handoffs and too much duplication: creative, medical communications, media, PR, social, congress, market access, CRM, data, production, influencer, patient support and local agencies.
Procurement has a critical role here. It should not only reduce cost. It should help design a partner ecosystem that is faster, more transparent, better governed and more measurable.
O — Organisation
Governance, processes and ways of working must speed up.
The bottleneck in healthcare marketing is often not strategy, its friction and flow. Approvals take too long. Review cycles are unclear. Data sits in silos. Global assets are not reused. Local teams recreate materials. Agencies duplicate work. Medical, legal and regulatory review arrives too late.
A better model has clear decision rights, cross-functional squads, earlier medical and regulatory involvement, pre-approved content modules, claims libraries, escalation rules and common campaign planning disciplines.
D — Data
Data is no longer a reporting output but a critical competitive weapon.
Pharma and healthcare marketers need better sources of insight across HCP behaviour, patient journeys, GEO & search, social, CRM, field activity, media, access, adherence, sentiment, congress engagement and commercial outcomes.
But the foundation is usually unglamorous: consistent taxonomies, clean metadata, permissioned data, KPI governance, tagging discipline, standard dashboards and shared definitions of performance.
If data is not structured, accessible and trusted, AI will amplify confusion rather than improve decisions.
U — Understanding culture
Culture is the hidden accelerator , when it’s right. A bad culture is the hidden brake.
The cultural shift is toward evidence-led experimentation: test, learn, document, scale. Teams need to become more comfortable with modular reuse, global-local collaboration, AI-assisted workflows, social listening, faster decision-making and clearer accountability.
The cultural question is: does the organisation reward activity, or does it reward learning and outcomes?
C — Costs
Cost pressure is increasing, but blunt cost-cutting will damage growth.
The opportunity is to optimise the marketing investment system: agency fees, production spend, content reuse, technology licences, media working/non-working ratios, duplicative local activity, congress investment, data subscriptions and AI tooling.
In healthcare, cost optimisation should be linked to value creation. What activities improve HCP engagement? Which content drives patient understanding? Which assets are reused? Which agencies are essential? Which technologies are underused? Which approval delays create hidden cost?
The best marketing procurement teams will move from price negotiation to ecosystem productivity.
T — Technology
Technology should serve the operating model, not the other way around.
Most pharma and healthcare organisations already have plenty of platforms: CRM, DAM, MLR systems, consent management, marketing automation, analytics, social listening, field-force tools, content management, medical information systems and media platforms.
The issue is often integration, adoption and governance.
The technology agenda should focus on practical acceleration: AI-assisted insight, content development, modular asset management, automated tagging, medical review workflow, consented customer engagement, unified measurement and knowledge management.
Technology only creates value when it is connected to vision, people, process, data and decision-making its not a silver bullet or “thing” in its own right.
What this means now
The next healthcare marketing model will not be purely in-house, agent driven, outsourced, automated, global or local.
It will be a bionic ecosystem that combines the best of talent (internal and external) and technology. It needs to be carefully designed, it won’t just “evolve” bottom up.
For CMOs, marketing operations leaders and procurement teams, the task is to redesign the system for a market where health information, medical evidence, consumer behaviour, media, technology and supply-chain economics are all moving at once.
That is the new marketing operating model challenge.
And it is accelerating.
If you would like to see case histories of our historical work with many leading Pharma and healthcare companies then please let us know. You can fill in the form below and we’ll be in touch.
Sources
- IQVIA Institute — The Global Use of Medicines 2025: Outlook to 2029. Used for global medicine spending growth and US market outlook.
- FDA — Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner. Used for US DTC advertising regulatory context.
- KFF — Tracking Poll on Health Information and Trust: Health Information and Advice on Social Media. Used for social media health information and influencer trust statistics.
- Digital Health Coalition — Predicting 2025 Trends. Used for pharma interest in generative AI, consumer marketing, patient support and patient customer experience.
- The Guardian — Iran war driving up medicine prices; NHS dependency on petrochemicals. Used for recent geopolitical, oil, logistics, petrochemical, API and medical-product cost pressure context.
- BMJ — Health information in the age of social media and influence. Used for risks around health influencers, commercialised health content and misinformation.
Contact us